Advances in the treatment of hypereosinophilic syndromes
10.3760/cma.j.issn.1673-4408.2020.11.004
- VernacularTitle:嗜酸性粒细胞增多综合征的治疗进展
- Author:
Litian XUAN
1
;
Rong LIU
Author Information
1. 首都儿科研究所附属儿童医院血液内科，北京 100020
- From:
International Journal of Pediatrics
2020;47(11):764-767
- CountryChina
- Language:Chinese
-
Abstract:
Hypereosinophilic syndromes(HES)are a heterogeneous group of disorders characterized by persistent overproduction of eosinophils in bone marrow, peripheral blood, and tissues, which can involve multiple tissues and organs at the same time.Eosinophils infiltration and medium release can lead to multiple organ damage.The choice of treatment options depend on clinical manifestations, laboratory test results, and mutation analysis.The purpose of this review is to summarize the current treatment of HES, including conventional therapies such as glucocorticoids, hydroxylurea, interferon-alpha, as well as small molecule targeted drugs led by tyrosine kinase inhibitors, interleukin-5 and its receptor targeted monoclonal antibodies.
